How I Invest
How I Invest

E373: What Most CIOs Get Wrong About Alpha

What if the best investment opportunities are the ones most investors avoid because they’re too hard, too small, or too inefficient to pursue? In this episode, I sit down with Raphael, Deputy CIO and Co-Leader of HighVista Strategies, to discuss the concept of “beautifully inefficient” markets and w

Featured Speakers

David Weisburd Host

Topics Discussed

Episode Summary

Executive Summary: The conversation centers on HighVista’s investment philosophy: finding “beautifully inefficient” markets that combine mispricing with repeatability, especially in lower middle market private equity, venture capital, and biotech. Rafi argues that alpha is most durable where markets are large, under-covered, and operationally hard, and that governance, specialization, and partnership matter more than broad diversification or market timing. He also highlights continuation vehicles and longer private-hold periods as key structural shifts.

Main Topics: Beautifully inefficient markets (Priority: 5/5): Rafi explains that the best opportunities are not merely inefficient but inefficient in a repeatable, durable way, allowing investors to build sustainable advantages over time. Market selection and TAM (Priority: 5/5): He emphasizes choosing markets with enough breadth and dispersion—typically thousands of securities or a trillion-dollar-scale opportunity set—while avoiding crowded, over-efficient segments. LPs, alpha, and governance (Priority: 5/5): The discussion frames alpha as additive and uncorrelated, but only valuable if LP governance, incentive alignment, and decision rights allow institutions to lean into it effectively. Private markets evolution and continuation vehicles (Priority: 4/5): Rafi argues private markets are more mature, exits are slower, DPI will be lower, and continuation vehicles are an important structural innovation for extending ownership of high-quality assets. Venture capital and strategic ignorance (Priority: 4/5): He describes venture as a power-law asset class where early conviction often looks irrational at first, making patience, contrarianism, and broad ecosystem access essential. Biotech as contrarian alpha (Priority: 4/5): Despite headwinds, he sees biotech as attractive because healthcare spend and pharmaceutical innovation should keep growing, creating bargains when the sector is out of favor. Diversification vs concentrated conviction (Priority: 5/5): Rafi argues that excessive diversification can be driven by agency risk, while better portfolios build enough breadth to support concentrated, high-conviction bets within a disciplined framework.

Key Arguments: Beautifully inefficient markets are preferable to merely inefficient ones because they offer both mispricing and persistence, making returns more durable and systematic. The ideal opportunity set is large enough to provide dispersion and many choices, but not so crowded or liquid that alpha is quickly arbitraged away. Institutional investors should focus first on governance, asset allocation, and diversification, then partner with specialists to generate additive alpha. Alpha is valuable because it is uncorrelated and can improve returns without materially increasing total portfolio risk. Lower middle market private equity remains attractive because it has better pricing, less competition, and more return on work than the large-cap end of the market. Continuation vehicles will increasingly be used not just to salvage struggling assets, but to retain and compound the best assets for longer periods. Private markets have matured, so investors should expect longer hold periods, lower DPI, and more emphasis on operational value creation and valuation discipline. Venture capital works because the best businesses often look strange early; success requires strategic ignorance, patient capital, and access to the right managers and deal flow. Biotech is attractive because healthcare and pharma innovation should take a growing share of GDP and healthcare spend, even though the sector is politically and sentiment-wise cyclical. Over-diversification often reflects principal-agent problems; more effective portfolios are diversified enough to enable concentrated upside where conviction is highest.

Data Points: HighVista AUM: $14 billion - Rafi is introduced as deputy CIO and co-lead of HighVista Strategies. Discussion horizon for durable opportunities: Years to a decade - He says great investment opportunities can last for years and sometimes up to a decade. Lower middle market private equity tailwind: 10–20 years - He cites the last 10 to 20 years as an excellent period for lower middle market private equity. U.S. stock market capitalization: $60 trillion+ - Used as an example of a very large TAM and opportunity universe. U.S. small-cap market cap: $2–3 trillion - He notes small caps make up only a small portion of total U.S. market capitalization. Small-cap share of U.S. market cap: ~5% - He contrasts number of companies with capitalization weight. Large U.S. tech platform valuations: Larger than virtually any country except the U.S., China, and Japan - Illustrates the scale of market concentration in the largest public companies. Private-market holding period: 10+1 to 14 years - LPs are reluctant to lock up capital for this long in blind pool structures. Swenson model private-market DPI: 24% - Referenced as historical DPI in the era of Yale-style endowment investing. 2024 private-market DPI: ~9% - Used to show how DPI has declined versus earlier eras. 2025 private-market DPI: ~9% - Indicates DPI remains subdued in the current environment. Continuation vehicle market size last year: $100 billion - Rafi cites growth and scale of the continuation vehicle market. HighVista venture history: Since the mid-1990s / 30 years - He notes the firm’s venture lineage dates back three decades. Healthcare cost share trend: Rising as GDP grows - He argues healthcare spending can grow faster than GDP over time. U.S. public vs private company universe: 3,000 public vs ~100,000 investable private companies - He uses this to argue private markets offer far more opportunity. Typical venture fund exit window: 10–15+ years - He says early-stage venture often takes the full term or longer to realize exits. Venture outcomes: 100x, 1,000x, or even 100,000x returns - Describes the power-law payoff profile in venture capital. Potential diversification effect: 1 to 9 investments cuts idiosyncratic risk by ~3x - Explains diversification through the square-root relationship. Potential diversification effect: 25 investments cuts idiosyncratic risk by ~5x - Illustrates diminishing marginal benefit of further diversification. Pension return predictability: 90% - Cites a study suggesting most pension performance is explained by asset allocation and sub-asset allocation.

Pivotal Quotes: "beautifully inefficient markets have the characteristic of having a great opportunity that hopefully persists for a reasonable period of time" — Rafi: Defines the core investment concept behind HighVista’s market selection framework. "alpha are things that are boring and hard" — Unnamed bank chairman (quoted by Rafi): Used to explain why enduring alpha often lives in difficult, less glamorous markets. "The market's shifted and investors are spending a lot of time thinking about that as opposed to, oh, let me just invest a large amount in private equity and the beta will take care of itself" — Rafi: Summarizes the new reality in private markets: more maturity, lower exits, and more need for active value creation.

Implications: Investors should prioritize governance, specialization, and patience over blanket diversification or simple beta bets. The biggest opportunities now appear in under-covered private and niche public markets where structural frictions create durable alpha.

🔓 Sign Up for Unlimited Episode Search

About How I Invest

How I Invest with David Weisburd is a podcast that interviews the world's leading institutional investors. Previous guests include The Ford Foundation, Northwestern University Endowment, CalPERS, Stepstone, and other top limited partners.

View all episodes from How I Invest